(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 5.12% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Charles River Laboratories International's revenue in 2024 is $4,129,409,000.On average, 6 Wall Street analysts forecast CRL's revenue for 2024 to be $216,570,838,661, with the lowest CRL revenue forecast at $215,703,951,844, and the highest CRL revenue forecast at $217,818,021,875. On average, 6 Wall Street analysts forecast CRL's revenue for 2025 to be $233,269,064,968, with the lowest CRL revenue forecast at $228,553,204,791, and the highest CRL revenue forecast at $235,944,490,685.
In 2026, CRL is forecast to generate $253,308,518,110 in revenue, with the lowest revenue forecast at $251,192,291,388 and the highest revenue forecast at $255,171,385,066.